sinc
random
control
trial
conduct
treatment
viral
pneumonia
antivir
immunomodul
immunocompet
adult
review
anecdot
experi
need
ration
use
agent
case
report
singl
case
seri
detail
treatment
outcom
english
literatur
review
pneumonia
caus
human
avian
influenza
viru
patient
varicella
zoster
viru
adenoviru
hantaviru
sar
coronaviru
sarscov
even
steroid
therapi
alon
mortal
rate
appear
lower
compar
conserv
treatment
pneumonia
caus
human
influenza
viru
vs
hantaviru
vs
combin
effect
antivir
acyclovir
steroid
treatment
varicella
zoster
viru
may
associ
lower
mortal
acyclovir
alon
vs
combin
interferon
plu
steroid
lopinavirritonavir
ribavirin
plu
steroid
associ
better
outcom
ribavirin
plu
steroid
vs
vs
respect
combin
lopinavirritonavir
plu
ribavirin
significantli
reduc
viru
load
sarscov
nasopharyng
serum
stool
urin
specimen
taken
day
symptom
onset
compar
histor
control
group
treat
ribavirin
appear
combin
effect
antivir
steroid
associ
better
outcom
random
therapeut
trial
conduct
ascertain
rel
use
antivir
alon
combin
steroid
start
new
millennium
mark
two
emerg
infecti
diseas
come
wild
game
food
anim
poultri
commun
acquir
pneumonia
respons
empir
treatment
antibacteri
cover
typic
atyp
agent
sarscov
avian
influenza
pneumonia
associ
signific
mortal
unfortun
prospect
studi
perform
document
viru
load
chang
cours
ill
respiratori
viral
pneumonia
literatur
histolog
chang
pathogenesi
condit
scarc
random
placebocontrol
treatment
trial
ever
conduct
lack
data
often
attribut
lack
rapid
diagnost
test
effect
antivir
sar
outbreak
empir
use
ribavirin
steroid
regard
controversi
due
explos
natur
outbreak
random
control
trial
treatment
could
organ
therefor
attempt
review
literatur
rational
strategi
use
treatment
acut
commun
acquir
viral
pneumonia
immunocompet
adult
viru
load
data
serolog
chang
acut
respiratori
viral
pneumonia
avail
literatur
well
sar
patient
includ
analysi
case
report
seri
clinic
detail
involv
medic
therapi
viral
pneumonia
includ
sar
patient
age
year
includ
review
patient
immunosuppress
condit
congenit
acquir
immunodefici
solid
marrow
transplant
undergo
chemotherapi
pregnanc
exclud
appropri
cite
bibliographi
also
retriev
analysi
preliminari
review
public
suggest
viral
pneumonia
caus
sarscov
constitut
major
case
report
literatur
howev
similar
caus
viral
pneumonia
littl
inform
viru
load
chang
respect
treatment
systemat
report
therefor
laboratori
data
cohort
sar
patient
fulfil
modifi
definit
retriev
viru
load
measur
nasopharyng
serum
stool
urin
specimen
taken
day
symptom
onset
part
data
previous
report
viru
load
result
correl
specif
antivir
regimen
name
ribavirin
without
lopinavirritonavir
sar
serial
quantit
rtpcr
igg
titer
sarscov
perform
randomli
select
patient
treat
ribavirin
corticosteroid
day
onset
symptom
compar
serial
viru
load
antibodi
seroconvers
respiratori
viru
infect
englishlanguag
literatur
search
identifi
studi
detail
descript
serial
viru
load
antibodi
titer
cours
infect
literatur
review
english
public
human
studi
identifi
pubm
combin
keyword
viru
pneumonia
treatment
sar
treatment
use
januari
respect
among
public
relat
hiv
aid
patient
cancer
transplant
patient
vaccin
immun
topic
exclud
remain
paper
retriev
analys
sar
paper
retriev
analys
subsequ
pubm
search
use
keyword
influenza
pneumonia
treatment
respiratori
syncyti
viru
pneumonia
treatment
varicella
pneumonia
treatment
adenoviru
pneumonia
treatment
hantaviru
pulmonari
syndrom
treatment
identifi
anoth
paper
respect
cite
bibliographi
relev
also
includ
review
howev
paper
contain
clinic
detail
inform
medic
treatment
viral
pneumonia
paper
sar
paper
respect
patient
nonsar
viral
pneumonia
case
report
seri
tabl
aetiolog
diagnos
human
influenza
viru
avian
influenza
viru
varicella
zoster
viru
vzv
adenoviru
hantaviru
respiratori
syncyti
viru
rsv
measl
viru
epsteinbarr
viru
ebv
document
combin
clinic
featur
radiograph
chang
virolog
serolog
test
demograph
detail
mention
patient
male
femal
median
age
year
rang
small
number
patient
suffer
pneumonia
caus
rsv
measl
ebv
preclud
meaning
analysi
discuss
agent
overal
mortal
rang
vzv
adenoviru
human
treatment
human
influenza
infect
antivir
agent
rimantadin
one
patient
oseltamivir
five
patient
combin
rimantadin
oseltamivir
use
median
day
rang
day
admiss
high
dose
corticosteroid
without
antivir
therapi
also
attempt
dose
steroid
rang
hydrocortison
mg
ivi
everi
hourli
methylprednisolon
mg
ivi
everi
hourli
amantadin
four
patient
oseltamivir
three
patient
combin
antivir
corticosteroid
three
patient
also
use
treatment
avian
influenza
infect
appar
benefit
sinc
antivir
agent
start
median
day
rang
day
admiss
corticosteroid
intraven
methylprednisolon
mgkg
everi
hourli
day
given
three
mechan
ventil
patient
two
die
acut
respiratori
distress
syndrom
ard
vzv
pneumonia
antivir
therapi
includ
intraven
acyclovir
mgkg
everi
hourli
day
initi
patient
two
patient
treat
vidarabin
widespread
use
acyclovir
corticosteroid
combin
acyclovir
patient
dosag
durat
steroid
quit
variabl
tabl
two
patient
receiv
intraven
immunoglobulin
ivig
togeth
intraven
acyclovir
favor
outcom
mortal
patient
receiv
acyclovir
vidarabin
alon
seven
wherea
four
patient
manag
support
care
die
one
patient
die
intraven
acyclovir
initi
within
day
admiss
death
patient
treat
combin
acyclovir
immunomodul
corticosteroid
ivig
adenovir
pneumonia
antivir
ever
use
treatment
two
four
patient
receiv
steroid
die
appear
higher
patient
manag
conserv
mortal
hantaviru
pulmonari
syndrom
treat
intraven
ribavirin
appear
slightli
lower
treat
conserv
use
methylprednisolon
associ
dramat
decreas
mortal
though
case
sar
treatment
detail
report
literatur
mani
patient
diagnos
accord
clinic
criteria
issu
without
laboratori
confirm
tabl
one
case
seri
includ
patient
treat
differ
treatment
regimen
aggreg
togeth
could
analys
male
femal
except
patient
treat
conserv
antivir
therapi
andor
immunomodul
therapi
given
patient
patient
receiv
specif
antivir
therapi
andor
immunomodul
therapi
treat
ribavirin
contain
regimen
treat
lopinavirritonavir
contain
regimen
initi
phase
diseas
immunomodul
therapi
without
antivir
agent
initi
patient
recombin
interferon
alpha
corticosteroid
combin
interferon
corticosteroid
use
case
respect
patient
receiv
treatment
clinic
deterior
ribavirin
oseltamivir
lopinavirritonavir
convalesc
plasma
given
rescu
medic
therapi
respect
high
dose
puls
methylprednisolon
use
clinic
deterior
oxygen
desatur
worsen
radiograph
infiltr
chest
recurr
fever
without
evid
nosocomi
sepsi
report
howev
number
patient
requir
puls
steroid
mention
furthermor
ivig
thymic
peptid
recombin
human
thymu
protein
use
patient
clinic
detail
suffici
meaning
analysi
overal
mortal
sar
case
obviou
differ
note
irrespect
whether
patient
treat
ribavirin
without
corticosteroid
corticosteroid
alon
recombin
interferonalpha
given
admiss
deterior
howev
mortal
group
patient
treat
lopinavirritonavir
ribavirin
corticosteroid
nine
patient
treat
interferon
corticosteroid
one
patient
receiv
convalesc
plasma
rescu
therapi
sar
patient
cohort
clinic
present
virolog
test
result
treatment
regimen
previous
report
viru
load
nasopharyng
serum
stool
urin
specimen
collect
day
onset
symptom
tabul
tabl
signific
relationship
viru
load
age
presenc
comorbid
howev
signific
decreas
viru
load
observ
lopinavirritonavir
ad
ribavirin
tabl
also
interest
note
stool
viru
load
significantli
higher
male
vs
log
copi
ml
wherea
urin
significantli
higher
femal
vs
log
copiesml
histor
control
treat
ribavirin
corticosteroid
randomli
select
patient
serial
viru
load
studi
perform
nasopharyng
specimen
mean
viru
load
log
copiesml
day
onset
symptom
respect
fig
declin
viru
load
nasopharyng
specimen
coincid
appear
igg
antibodi
titer
sarscov
cours
infect
fig
sinc
similar
clinic
studi
respiratori
viral
pneumonia
avail
literatur
except
natur
occur
case
influenza
anoth
case
experiment
infect
rsv
artifici
inocul
healthi
volunt
adopt
comparison
fig
viru
load
influenza
viru
rsv
peak
day
respect
wherea
sarscov
occur
day
onset
symptom
fig
antibodi
respons
baselin
antibodi
influenza
viru
rsv
detect
serum
nasal
wash
antibodi
sarscov
present
day
symptom
onset
despit
exhaust
laboratori
investig
aetiolog
agent
could
identifi
around
half
patient
suffer
acut
commun
acquir
pneumonia
immunocompet
adult
commun
acquir
pneumonia
pyogen
bacteria
still
constitut
major
microbiolog
document
agent
prospect
studi
lack
readili
avail
rapid
diagnost
test
respiratori
viral
infect
one
major
reason
lack
report
natur
histori
pathogenesi
treatment
viral
pneumonia
welldocu
treatment
regimen
random
control
trial
avail
hiv
hcv
hbv
hsv
vzv
cmv
human
influenza
without
pneumonia
moreov
vitro
suscept
virus
may
correl
clinic
efficaci
case
interferonalpha
use
treatment
genit
herp
improv
symptom
score
durat
genit
lesion
found
irrespect
whether
system
topic
interferonalpha
use
case
acut
rsv
bronchiol
efficaci
aerosol
ribavirin
also
question
due
lack
effect
antivir
therapi
viral
pneumonia
altern
strategi
use
immunomodul
propos
earli
unexpect
sinc
cytotox
cell
respons
may
lead
immunopatholog
damag
initi
period
host
damag
mediat
viru
induc
cytolysi
present
literatur
review
suggest
least
case
human
influenza
viru
hantaviru
pneumonia
steroid
therapi
alon
may
improv
outcom
case
vzv
pneumonia
absenc
mortal
case
treat
addit
steroid
efficaci
antivir
agent
acyclovir
seem
support
approach
despit
decreas
mortal
patient
vs
ribavirin
consid
effect
antivir
hantaviru
howev
use
steroid
phase
sever
ard
hantaviru
pulmonari
syndrom
may
associ
reduct
mortal
vs
emphas
group
report
cluster
adenovir
pneumonia
use
high
dose
steroid
without
effect
antivir
may
actual
increas
mortal
howev
number
adenovir
pneumonia
treat
steroid
small
justifi
conclus
overal
dosag
durat
steroid
therapi
viral
pneumonia
extrem
heterogen
futur
random
clinic
studi
conduct
ascertain
dosag
durat
steroid
associ
least
complic
includ
secondari
infect
avascular
necrosi
bone
anoth
difficulti
manag
viral
pneumonia
earli
peak
viru
load
leav
narrow
window
opportun
antivir
treatment
human
influenza
rsv
viru
load
peak
around
day
symptom
onset
natur
experiment
infect
healthi
adult
fig
earli
control
viru
load
two
infect
may
explain
brisk
antibodi
respons
possibl
due
previou
antigen
exposur
fig
complet
differ
pictur
emerg
case
sar
viru
load
sar
patient
peak
around
day
larg
area
curv
compar
human
influenza
viru
rsv
fig
onset
antibodi
respons
also
delay
start
appear
around
day
failur
innat
immun
rel
delay
onset
adapt
antibodi
respons
control
viru
replic
may
explan
high
mortal
infect
previou
studi
show
mortal
directli
relat
viru
load
nasopharyng
specimen
admiss
day
mortal
also
correl
number
rtpcr
posit
specimen
differ
bodi
site
includ
nasopharyng
serum
stool
urin
therefor
effect
antivir
could
reduc
peak
viru
load
area
curv
key
success
treatment
sar
perhap
avian
influenza
viru
sinc
gener
popul
immunolog
memori
toward
two
virus
intraven
ribavirin
empir
use
broadspectrum
antivir
agent
begin
sar
epidem
mani
countri
ribavirin
select
broadspectrum
antivir
activ
possibl
interfer
cellular
inosin
monophosph
dehydrogenas
shown
effect
mous
coronaviru
set
fulmin
murin
hepat
although
vitro
antivir
activ
ribavirin
weak
indirect
immunomodulatori
activ
decreas
releas
proinflammatori
cytokin
macrophag
mice
may
also
switch
immun
respons
mice
respons
benefici
intracellular
infect
subsequ
vitro
suscept
test
suggest
antivir
effect
could
achiev
high
concentr
difficult
achiev
clinic
despit
fact
ribavirin
known
concentr
cell
line
african
green
monkey
kidney
vero
mous
cell
moreov
use
high
dose
regimen
indic
treatment
haemorrhag
fever
associ
signific
hemolysi
thu
option
dilig
search
epidem
lopinavirritonavir
use
addit
ribavirin
weak
vitro
antivir
activ
prototyp
sarscov
checkerboard
assay
demonstr
synergisim
lopinavir
figur
chang
titer
serum
antibodi
influenza
viru
nasal
iga
rsv
igg
sarscov
onset
symptom
serum
antibodi
titer
hai
influenza
viru
determin
use
serial
sera
patient
natur
infect
influenza
viru
patient
shown
fig
mean
rsv
nasal
iga
titer
obtain
nasal
wash
subject
inocul
rsv
group
patient
shown
fig
mean
igg
titer
sarscov
obtain
use
sera
patient
infect
sarscov
group
patient
shown
fig
ribavirin
low
viral
inoculum
report
suggest
glycyrrhizin
interferon
beta
betaferon
interferon
alpha
wellferon
interferon
alpha
alferon
leucocyt
interferon
alpha
baicalin
may
also
vitro
activ
howev
interferon
consid
clinician
epidem
known
proinflammatori
activ
may
potenti
inflammatori
damag
initi
viral
infect
report
side
effect
interstiti
pneumon
bronchiol
obliteran
organ
pneumonia
subsequ
pegyl
recombin
interferon
alpha
shown
effect
preexposur
perhap
earli
postexposur
prophylaxi
cynomolgu
macaqu
macaca
fasciculari
experiment
infect
sarscov
though
differ
prepar
interferon
appear
effect
vitro
recombin
interferon
alpha
interferon
use
sar
patient
moreov
still
earli
suggest
interferon
like
effect
human
trial
contradictori
report
vitro
suscept
test
report
interferon
beta
interferon
alpha
review
summar
anecdot
report
treatment
viral
pneumonia
find
may
bias
sinc
posit
result
like
report
steroid
appear
confer
benefit
patient
ard
due
hantaviru
human
influenza
viru
vzv
howev
earli
use
high
dose
steroid
may
counterproduct
absenc
effect
antivir
agent
random
placebo
control
trial
util
differ
regimen
antivir
without
steroid
consid
treatment
sar
viral
pneumonia
futur
